Artivion, Inc.
$21.17
The Read: Artivion’s stock surged about 54% after FDA approval of its NEXUS Aortic Arch System despite in-line EPS, but later fell over 9% following lowered revenue guidance and a securities fraud investigation that overshadowed a Q1 earnings beat.
Price
Overlays
Panel
AORT
Hover to view data
No Data